{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T11:08:59Z","timestamp":1779361739914,"version":"3.51.4"},"publisher-location":"Cham","reference-count":171,"publisher":"Springer Nature Switzerland","isbn-type":[{"value":"9783032214140","type":"print"},{"value":"9783032214157","type":"electronic"}],"license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026]]},"DOI":"10.1007\/978-3-032-21415-7_12","type":"book-chapter","created":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T10:10:40Z","timestamp":1779358240000},"page":"911-943","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Imaging Immunotherapy"],"prefix":"10.1007","author":[{"given":"Egesta","family":"Lopci","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angelo","family":"Castello","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matteo","family":"Caracciolo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luigi","family":"Mansi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akram","family":"Al-Ibraheem","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,5,22]]},"reference":[{"issue":"S5","key":"12_CR1","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.1053\/j.seminoncol.2014.09.004","volume":"41","author":"ML Disis","year":"2014","unstructured":"Disis ML (2014) Mechanism of action of immunotherapy. Semin Oncol 41(S5):S3\u2013S13","journal-title":"Semin Oncol"},{"issue":"7378","key":"12_CR2","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1038\/nature10673","volume":"480","author":"I Mellman","year":"2011","unstructured":"Mellman I, Coukos G, Dranoff G (2011) Cancer immunotherapy comes of age. Nature [Internet] 480(7378):480\u2013489","journal-title":"Nature [Internet]"},{"issue":"23","key":"12_CR3","doi-asserted-by":"publisher","first-page":"5675","DOI":"10.3390\/cancers15235675","volume":"15","author":"EM Abenavoli","year":"2023","unstructured":"Abenavoli EM, Linguanti F, Calabretta R, Delgado Bolton RC, Berti V, Lopci E (2023) Clinical application of ImmunoPET targeting checkpoint inhibitors. Cancers (Basel) 15(23):5675","journal-title":"Cancers (Basel)"},{"key":"12_CR4","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1038\/nrc3239","volume":"12","author":"DM Pardoll","year":"2012","unstructured":"Pardoll DM (2012) The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 12:252\u2013264","journal-title":"Nat Rev Cancer"},{"key":"12_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2023.102614","volume":"120","author":"M Borgeaud","year":"2023","unstructured":"Borgeaud M, Sandoval J, Obeid M, Banna G, Michielin O, Addeo A, Friedlaender A (2023) Novel targets for immune-checkpoint inhibition in cancer. Cancer Treat Rev 120:102614","journal-title":"Cancer Treat Rev"},{"issue":"6","key":"12_CR6","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1038\/nrclinonc.2016.36","volume":"13","author":"HJ Jackson","year":"2016","unstructured":"Jackson HJ, Rafiq S, Brentjens RJ (2016) Driving CAR T-cells forward. Nat Rev Clin Oncol [Internet] 13(6):370\u2013383","journal-title":"Nat Rev Clin Oncol [Internet]"},{"issue":"19","key":"12_CR7","doi-asserted-by":"publisher","first-page":"4700","DOI":"10.3390\/cancers14194700","volume":"14","author":"F Linguanti","year":"2022","unstructured":"Linguanti F, Abenavoli EM, Berti V, Lopci E (2022) Metabolic imaging in B-cell lymphomas during CAR-T cell therapy. Cancers (Basel) 14(19):4700","journal-title":"Cancers (Basel)"},{"issue":"4","key":"12_CR8","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1016\/j.cpet.2024.05.006","volume":"19","author":"EM Abenavoli","year":"2024","unstructured":"Abenavoli EM, Linguanti F, Dercle L, Berti V, Lopci E (2024) FDG-PET\/CT imaging in chimeric antigen receptor-engineered T-cell treatment in patients with B-cell lymphoma: current evidence. PET Clin 19(4):505\u2013513","journal-title":"PET Clin"},{"issue":"1","key":"12_CR9","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/s41571-023-00832-4","volume":"21","author":"SM Albelda","year":"2024","unstructured":"Albelda SM (2024) CAR T cell therapy for patients with solid tumours: key lessons to learn and unlearn. Nat Rev Clin Oncol 21(1):47\u201366","journal-title":"Nat Rev Clin Oncol"},{"issue":"4","key":"12_CR10","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.3390\/cancers15041063","volume":"15","author":"A Al-Ibraheem","year":"2023","unstructured":"Al-Ibraheem A, Abdlkadir AS, Juweid ME, Al-Rabi K, Ma\u2019koseh M, Abdel-Razeq H, Mansour A (2023) FDG-PET\/CT in the monitoring of lymphoma immunotherapy response: current status and future prospects. Cancers (Basel) 15(4):1063","journal-title":"Cancers (Basel)"},{"key":"12_CR11","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R et al (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45:228\u2013247","journal-title":"Eur J Cancer"},{"key":"12_CR12","doi-asserted-by":"publisher","first-page":"7412","DOI":"10.1158\/1078-0432.CCR-09-1624","volume":"15","author":"JD Wolchok","year":"2009","unstructured":"Wolchok JD, Hoos A, O\u2019Day S, Weber JS, Hamid O, Lebbe C et al (2009) Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res 15:7412\u20137420","journal-title":"Clin Cancer Res"},{"key":"12_CR13","doi-asserted-by":"publisher","first-page":"3936","DOI":"10.1158\/1078-0432.CCR-13-0895","volume":"19","author":"M Nishino","year":"2013","unstructured":"Nishino M, Giobbie-Hurder A, Gargano M, Suda M, Ramaiya NH, Hodi FS (2013) Developing a common language for tumor response to immunotherapy: immune-related response criteria using unidimensional measurements. Clin Cancer Res 19:3936\u20133943","journal-title":"Clin Cancer Res"},{"key":"12_CR14","doi-asserted-by":"publisher","first-page":"e143","DOI":"10.1016\/S1470-2045(17)30074-8","volume":"18","author":"L Seymour","year":"2017","unstructured":"Seymour L, Bogaerts J, Perrone A et al (2017) iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics. Lancet Oncol 18:e143\u2013e152","journal-title":"Lancet Oncol"},{"issue":"7","key":"12_CR15","doi-asserted-by":"publisher","first-page":"2323","DOI":"10.1007\/s00259-022-05780-2","volume":"49","author":"E Lopci","year":"2022","unstructured":"Lopci E, Hicks RJ, Dimitrakopoulou-Strauss A, Dercle L, Iravani A, Seban RD, Sachpekidis C, Humbert O, Gheysens O, Glaudemans AWJM, Weber W, Wahl RL, Scott AM, Pandit-Taskar N, Aide N (2022) Joint EANM\/SNMMI\/ANZSNM practice guidelines\/procedure standards on recommended use of [18F]FDG PET\/CT imaging during immunomodulatory treatments in patients with solid tumors version 1.0. Eur J Nucl Med Mol Imaging 49(7):2323\u20132341","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"1","key":"12_CR16","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1007\/s00259-018-4171-4","volume":"46","author":"N Aide","year":"2019","unstructured":"Aide N, Hicks RJ, Le Tourneau C, Lheureux S, Fanti S, Lopci E (2019) FDG PET\/CT for assessing tumour response to immunotherapy: report on the EANM symposium on immune modulation and recent review of the literature. Eur J Nucl Med Mol Imaging 46(1):238\u2013250","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"1","key":"12_CR17","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1148\/radiol.210518","volume":"306","author":"L Dercle","year":"2023","unstructured":"Dercle L, Sun S, Seban RD, Mekki A, Sun R, Tselikas L, Hans S, Bernard-Tessier A, Mihoubi Bouvier F, Aide N, Vercellino L, Rivas A, Girard A, Mokrane FZ, Manson G, Houot R, Lopci E, Yeh R, Ammari S, Schwartz LH (2023) Emerging and evolving concepts in cancer immunotherapy imaging. Radiology 306(1):32\u201346","journal-title":"Radiology"},{"key":"12_CR18","doi-asserted-by":"publisher","first-page":"1049043","DOI":"10.3389\/fimmu.2022.1049043","volume":"13","author":"Y Gao","year":"2022","unstructured":"Gao Y, Wu C, Chen X, Ma L, Zhang X, Chen J, Liao X, Liu M (2022) PET\/CT molecular imaging in the era of immune-checkpoint inhibitors therapy. Front Immunol 13:1049043","journal-title":"Front Immunol"},{"issue":"11","key":"12_CR19","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0109866","volume":"9","author":"K Higashikawa","year":"2014","unstructured":"Higashikawa K, Yagi K, Watanabe K, Kamino S, Ueda M, Hiromura M, Enomoto S (2014) 64Cu-DOTA-anti-CTLA-4 mAb enabled PET visualization of CTLA-4 on the T-cell infiltrating tumor tissues. PLoS One 9(11):e109866","journal-title":"PLoS One"},{"issue":"12","key":"12_CR20","doi-asserted-by":"publisher","first-page":"1852","DOI":"10.1038\/s41591-018-0255-8","volume":"24","author":"F Bensch","year":"2018","unstructured":"Bensch F, van der Veen EL, Lub-de Hooge MN, Jorritsma-Smit A, Boellaard R, Kok IC, Oosting SF, Schr\u00f6der CP, Hiltermann TJN, van der Wekken AJ et al (2018) 89Zr-atezolizumab imaging as a non-invasive approach to assess clinical response to PD-L1 blockade in cancer. Nat Med 24(12):1852\u20131858","journal-title":"Nat Med"},{"issue":"1","key":"12_CR21","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.annonc.2021.10.213","volume":"33","author":"IC Kok","year":"2022","unstructured":"Kok IC, Hooiveld JS, van de Donk PP, Giesen D, van der Veen EL, Lub-de Hooge MN, Brouwers AH, Hiltermann TJN, van der Wekken AJ, Hijmering-Kappelle LBM et al (2022) 89Zr-pembrolizumab imaging as a non-invasive approach to assess clinical response to PD-1 blockade in cancer. Ann Oncol 33(1):80\u201388","journal-title":"Ann Oncol"},{"issue":"3","key":"12_CR22","doi-asserted-by":"publisher","first-page":"362","DOI":"10.2967\/jnumed.121.261926","volume":"63","author":"AN Niemeijer","year":"2022","unstructured":"Niemeijer AN, Oprea-Lager DE, Huisman MC, Hoekstra OS, Boellaard R, de Wit-van der Veen BJ, Bahce I, Vugts DJ, van Dongen GAMS, Thunnissen E et al (2022) Study of 89Zr-Pembrolizumab PET\/CT in patients with advanced-stage non-small cell lung cancer. J Nucl Med 63(3):362\u2013367","journal-title":"J Nucl Med"},{"issue":"3","key":"12_CR23","doi-asserted-by":"publisher","first-page":"738","DOI":"10.3390\/cancers12030738","volume":"12","author":"RK Vaddepally","year":"2020","unstructured":"Vaddepally RK, Kharel P, Pandey R, Garje R, Chandra AB (2020) Review of indications of FDA-approved immune check-point inhibitors per NCCN guidelines with the level of evidence. Cancers (Basel) 12(3):738","journal-title":"Cancers (Basel)"},{"key":"12_CR24","unstructured":"https:\/\/ascopubs.org\/doi\/10.1200\/JCO.2024.42.16_suppl.11057"},{"key":"12_CR25","unstructured":"https:\/\/ascopubs.org\/doi\/10.1200\/JCO.2019.37.15_suppl.e14062"},{"issue":"22","key":"12_CR26","doi-asserted-by":"publisher","first-page":"6958","DOI":"10.1158\/1078-0432.CCR-11-1595","volume":"17","author":"EJ Lipson","year":"2011","unstructured":"Lipson EJ, Drake CG (2011) Ipilimumab: an anti-CTLA-4 antibody for metastatic melanoma. Clin Cancer Res 17(22):6958\u20136962","journal-title":"Clin Cancer Res"},{"issue":"2","key":"12_CR27","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/j.ejca.2011.09.018","volume":"48","author":"Z Hanaizi","year":"2012","unstructured":"Hanaizi Z, van Zwieten-Boot B, Calvo G, Lopez AS, van Dartel M, Camarero J, Abadie E, Pignatti F (2012) The European medicines agency review of ipilimumab (Yervoy) for the treatment of advanced (unresectable or metastatic) melanoma in adults who have received prior therapy: summary of the scientific assessment of the Committee for Medicinal Products for human use. Eur J Cancer 48(2):237\u2013242","journal-title":"Eur J Cancer"},{"issue":"1","key":"12_CR28","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.phrs.2011.09.002","volume":"65","author":"G Graziani","year":"2012","unstructured":"Graziani G, Tentori L, Navarra P (2012) Ipilimumab: a novel immunostimulatory monoclonal antibody for the treatment of cancer. Pharmacol Res 65(1):9\u201322","journal-title":"Pharmacol Res"},{"issue":"13","key":"12_CR29","doi-asserted-by":"publisher","first-page":"2310","DOI":"10.1007\/s00259-017-3802-5","volume":"44","author":"S Rossi","year":"2017","unstructured":"Rossi S, Toschi L, Castello A, Grizzi F, Mansi L, Lopci E (2017) Clinical characteristics of patient selection and imaging predictors of outcome in solid tumors treated with checkpoint-inhibitors. Eur J Nucl Med Mol Imaging 44(13):2310\u20132325","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"12_CR30","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1007\/978-981-15-3266-5_2","volume":"1248","author":"S Van Coillie","year":"2020","unstructured":"Van Coillie S, Wiernicki B, Xu J (2020) Molecular and cellular functions of CTLA-4. Adv Exp Med Biol 1248:7\u201332. https:\/\/doi.org\/10.1007\/978-981-15-3266-5_2","journal-title":"Adv Exp Med Biol"},{"key":"12_CR31","doi-asserted-by":"publisher","first-page":"1198365","DOI":"10.3389\/fimmu.2023.1198365","volume":"14","author":"MM Hossen","year":"2023","unstructured":"Hossen MM, Ma Y, Yin Z, Xia Y, Du J, Huang JY, Huang JJ, Zou L, Ye Z, Huang Z (2023) Current understanding of CTLA-4: from mechanism to autoimmune diseases. Front Immunol 14:1198365","journal-title":"Front Immunol"},{"issue":"1","key":"12_CR32","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1097\/COC.0000000000000239","volume":"39","author":"EI Buchbinder","year":"2016","unstructured":"Buchbinder EI, Desai A (2016) CTLA-4 and PD-1 pathways: similarities, differences, and implications of their inhibition. Am J Clin Oncol 39(1):98\u2013106","journal-title":"Am J Clin Oncol"},{"issue":"1","key":"12_CR33","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1182\/blood-2017-06-741033","volume":"131","author":"B Rowshanravan","year":"2018","unstructured":"Rowshanravan B, Halliday N, Sansom DM (2018) CTLA-4: a moving target in immunotherapy. Blood 131(1):58\u201367","journal-title":"Blood"},{"issue":"5","key":"12_CR34","doi-asserted-by":"publisher","first-page":"3044","DOI":"10.3390\/curroncol29050247","volume":"29","author":"Y Shiravand","year":"2022","unstructured":"Shiravand Y, Khodadadi F, Kashani SMA, Hosseini-Fard SR, Hosseini S, Sadeghirad H, Ladwa R, O\u2019Byrne K, Kulasinghe A (2022) Immune checkpoint inhibitors in cancer therapy. Curr Oncol 29(5):3044\u20133060","journal-title":"Curr Oncol"},{"issue":"3","key":"12_CR35","first-page":"727","volume":"10","author":"Y Han","year":"2020","unstructured":"Han Y, Liu D, Li L (2020) PD-1\/PD-L1 pathway: current researches in cancer. Am J Cancer Res 10(3):727\u2013742","journal-title":"Am J Cancer Res"},{"issue":"1-2","key":"12_CR36","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.vetimm.2009.10.006","volume":"134","author":"A Folkl","year":"2010","unstructured":"Folkl A, Bienzle D (2010) Structure and function of programmed death (PD) molecules. Vet Immunol Immunopathol 134(1-2):33\u201338","journal-title":"Vet Immunol Immunopathol"},{"issue":"4","key":"12_CR37","first-page":"1553","volume":"5","author":"H Yamane","year":"2015","unstructured":"Yamane H, Isozaki H, Takeyama M, Ochi N, Kudo K, Honda Y, Yamagishi T, Kubo T, Kiura K, Takigawa N (2015) Programmed cell death protein 1 and programmed death-ligand 1 are expressed on the surface of some small-cell lung cancer lines. Am J Cancer Res 5(4):1553\u20131557","journal-title":"Am J Cancer Res"},{"key":"12_CR38","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.568931","volume":"11","author":"K Hudson","year":"2020","unstructured":"Hudson K, Cross N, Jordan-Mahy N, Leyland R (2020) The extrinsic and intrinsic roles of PD-L1 and its receptor PD-1: implications for immunotherapy treatment. Front Immunol 11:568931","journal-title":"Front Immunol"},{"key":"12_CR39","doi-asserted-by":"publisher","first-page":"2521","DOI":"10.1056\/NEJMoa1503093","volume":"372","author":"C Robert","year":"2015","unstructured":"Robert C, Schachter J, Long GV, Arance A, Grob JJ, Mortier L et al (2015) Pembrolizumab versus Ipilimumab in advanced Melanoma. N Engl J Med 372:2521\u20132532","journal-title":"N Engl J Med"},{"key":"12_CR40","doi-asserted-by":"publisher","first-page":"1328","DOI":"10.1056\/NEJMoa1917346","volume":"383","author":"RS Herbst","year":"2020","unstructured":"Herbst RS, Giaccone G, de Marinis F, Reinmuth N, Vergnenegre A, Barrios CH et al (2020) Atezolizumab for first-line treatment of PD-L1\u2013selected patients with NSCLC. N Engl J Med 383:1328\u20131339","journal-title":"N Engl J Med"},{"key":"12_CR41","doi-asserted-by":"publisher","first-page":"1374","DOI":"10.1016\/S1470-2045(16)30364-3","volume":"17","author":"HL Kaufman","year":"2016","unstructured":"Kaufman HL, Russell J, Hamid O, Bhatia S, Terheyden P, D\u2019Angelo SP et al (2016) Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial. Lancet Oncol 17:1374\u20131385","journal-title":"Lancet Oncol"},{"key":"12_CR42","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1146\/annurev-pathol-042020-042741","volume":"16","author":"S Bagchi","year":"2021","unstructured":"Bagchi S, Yuan R, Engleman EG (2021) Immune checkpoint inhibitors for the treatment of cancer: clinical impact and mechanisms of response and resistance. Annu Rev Pathol 16:223\u2013249","journal-title":"Annu Rev Pathol"},{"issue":"5","key":"12_CR43","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1001\/jamaoncol.2020.7684","volume":"7","author":"C Valero","year":"2021","unstructured":"Valero C, Lee M, Hoen D, Zehir A, Berger MF, Seshan VE, Chan TA, Morris LGT (2021) Response rates to anti-PD-1 immunotherapy in microsatellite-stable solid tumors with 10 or more mutations per Megabase. JAMA Oncol 7(5):739\u2013743","journal-title":"JAMA Oncol"},{"issue":"7","key":"12_CR44","doi-asserted-by":"publisher","first-page":"2483","DOI":"10.1007\/s00262-023-03441-3","volume":"72","author":"Y Mao","year":"2023","unstructured":"Mao Y, Xie H, Lv M, Yang Q, Shuang Z, Gao F, Li S, Zhu L, Wang W (2023) The landscape of objective response rate of anti-PD-1\/L1 monotherapy across 31 types of cancer: a system review and novel biomarker investigating. Cancer Immunol Immunother 72(7):2483\u20132498","journal-title":"Cancer Immunol Immunother"},{"issue":"1","key":"12_CR45","first-page":"zcad012","volume":"5","author":"J Chen","year":"2023","unstructured":"Chen J, Rebibo D, Cao J, Mok SY, Patel N, Tseng PC, Zhang Z, Yip KY (2023) ICI efficacy information portal: a knowledgebase for responder prediction to immune checkpoint inhibitors. NAR. Cancer 5(1):zcad012","journal-title":"Cancer"},{"issue":"21","key":"12_CR46","doi-asserted-by":"publisher","first-page":"2018","DOI":"10.1056\/NEJMoa1501824","volume":"372","author":"EB Garon","year":"2015","unstructured":"Garon EB, Rizvi NA, Hui R, Leighl N, Balmanoukian AS et al (2015) Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med 372(21):2018\u20132028","journal-title":"N Engl J Med"},{"issue":"4","key":"12_CR47","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1200\/JCO.2018.78.2276","volume":"37","author":"PA Ott","year":"2019","unstructured":"Ott PA, Bang Y-J, Piha-Paul SA, Razak ARA, Bennouna J et al (2019) T-cell-inflamed gene-expression profile, programmed death ligand 1 expression, and tumor mutational burden predict efficacy in patients treated with pembrolizumab across 20 cancers: KEYNOTE-028. J Clin Oncol 37(4):318\u2013327","journal-title":"J Clin Oncol"},{"key":"12_CR48","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1200\/JCO.2017.75.1644","volume":"36","author":"FS Hodi","year":"2018","unstructured":"Hodi FS, Ballinger M, Lyons B, Soria JC, Nishino M, Tabernero J et al (2018) Immune-modified response evaluation criteria in solid tumors (imRECIST): refining guidelines to assess the clinical benefit of cancer immunotherapy. J Clin Oncol 36:850\u2013858","journal-title":"J Clin Oncol"},{"issue":"13","key":"12_CR49","doi-asserted-by":"publisher","first-page":"1773","DOI":"10.1016\/S0959-8049(99)00229-4","volume":"35","author":"H Young","year":"1999","unstructured":"Young H, Baum R, Cremerius U, Herholz K, Hoekstra O, Lammertsma AA, Pruim J, Price P (1999) Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of cancer (EORTC) PET study group. Eur J Cancer 35(13):1773\u20131782","journal-title":"Eur J Cancer"},{"issue":"Suppl 1","key":"12_CR50","doi-asserted-by":"publisher","first-page":"122S","DOI":"10.2967\/jnumed.108.057307","volume":"50","author":"RL Wahl","year":"2009","unstructured":"Wahl RL, Jacene H, Kasamon Y, Lodge MA (2009) From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors. J Nucl Med 50(Suppl 1):122S\u2013150S","journal-title":"J Nucl Med"},{"key":"12_CR51","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.2967\/jnumed.116.188839","volume":"58","author":"SY Cho","year":"2017","unstructured":"Cho SY, Lipson EJ, Im HJ, Rowe SP, Gonzalez EM, Blackford A et al (2017) Prediction of response to immune checkpoint inhibitor therapy using early-time-point (18)F-FDG PET\/CT imaging in patients with advanced melanoma. J Nucl Med 58:1421\u20131428","journal-title":"J Nucl Med"},{"key":"12_CR52","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1007\/s00259-017-3870-6","volume":"45","author":"H Anwar","year":"2018","unstructured":"Anwar H, Sachpekidis C, Winkler J, Kopp-Schneider A, Haberkorn U, Hassel JC et al (2018) Absolute number of new lesions on (18)F-FDG PET\/CT is more predictive of clinical response than SUV changes in metastatic melanoma patients receiving ipilimumab. Eur J Nucl Med Mol Imaging 45:376\u2013383","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"12_CR53","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/s13550-019-0473-1","volume":"9","author":"L Goldfarb","year":"2019","unstructured":"Goldfarb L, Duchemann B, Chouahnia K, Zelek L, Soussan M (2019) Monitoring anti-PD-1-based immunotherapy in non-small cell lung cancer with FDG PET: introduction of iPERCIST. EJNMMI Res 9:8","journal-title":"EJNMMI Res"},{"key":"12_CR54","doi-asserted-by":"publisher","first-page":"335","DOI":"10.2967\/jnumed.118.213652","volume":"60","author":"K Ito","year":"2019","unstructured":"Ito K, Teng R, Schoder H, Humm JL, Ni A, Michaud L et al (2019) (18)F-FDG PET\/CT for monitoring of ipilimumab therapy in patients with metastatic melanoma. J Nucl Med 60:335\u2013341","journal-title":"J Nucl Med"},{"issue":"5","key":"12_CR55","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1007\/s00259-020-04702-4","volume":"47","author":"N Aide","year":"2020","unstructured":"Aide N, De Pontdeville M, Lopci E (2020) Evaluating response to immunotherapy with 18F-FDG PET\/CT: where do we stand? Eur J Nucl Med Mol Imaging 47(5):1019\u20131021","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"1","key":"12_CR56","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1186\/s41747-020-00190-1","volume":"4","author":"M Unterrainer","year":"2020","unstructured":"Unterrainer M, Ruzicka M, Fabritius MP, Mittlmeier LM, Winkelmann M, R\u00fcbenthaler J, Brendel M, Subklewe M, von Bergwelt-Baildon M, Ricke J, Kunz WG, Cyran CC (2020) PET\/CT imaging for tumour response assessment to immunotherapy: current status and future directions. Eur Radiol Exp 4(1):63","journal-title":"Eur Radiol Exp"},{"issue":"2","key":"12_CR57","doi-asserted-by":"publisher","first-page":"175","DOI":"10.23736\/S1824-4785.20.03251-3","volume":"64","author":"A Castello","year":"2020","unstructured":"Castello A, Lopci E (2020) Update on tumor metabolism and patterns of response to immunotherapy. Q J Nucl Med Mol Imaging 64(2):175\u2013185","journal-title":"Q J Nucl Med Mol Imaging"},{"issue":"21","key":"12_CR58","doi-asserted-by":"publisher","first-page":"5160","DOI":"10.3390\/jcm10215160","volume":"10","author":"E Lopci","year":"2021","unstructured":"Lopci E (2021) Immunotherapy monitoring with immune checkpoint inhibitors based on [18F]FDG PET\/CT in metastatic melanomas and lung cancer. J Clin Med 10(21):5160","journal-title":"J Clin Med"},{"issue":"8","key":"12_CR59","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1007\/s00259-018-3972-9","volume":"45","author":"C Sachpekidis","year":"2018","unstructured":"Sachpekidis C, Anwar H, Winkler J, Kopp-Schneider A, Larribere L, Haberkorn U, Hassel JC, Dimitrakopoulou-Strauss A (2018) The role of interim 18F-FDG PET\/CT in prediction of response to ipilimumab treatment in metastatic melanoma. Eur J Nucl Med Mol Imaging 45(8):1289\u20131296","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"2","key":"12_CR60","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1148\/radiol.212481","volume":"304","author":"DJ Hughes","year":"2022","unstructured":"Hughes DJ, Subesinghe M, Taylor B, Bille A, Spicer J, Papa S, Goh V, Cook GJR (2022) 18F FDG PET\/CT and novel molecular imaging for directing immunotherapy in cancer. Radiology 304(2):246\u2013264","journal-title":"Radiology"},{"issue":"12","key":"12_CR61","doi-asserted-by":"publisher","first-page":"3696","DOI":"10.1007\/s00259-024-06794-8","volume":"51","author":"M Masse","year":"2024","unstructured":"Masse M, Chardin D, Tricarico P, Ferrari V, Martin N, Otto J, Darcourt J, Comte V, Humbert O (2024) [18F]FDG-PET\/CT atypical response patterns to immunotherapy in non-small cell lung cancer patients: long term prognosis assessment and clinical management proposal. Eur J Nucl Med Mol Imaging 51(12):3696\u20133708","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"12_CR62","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2024.102536","volume":"70","author":"P Gougis","year":"2024","unstructured":"Gougis P, Jochum F, Abbar B, Dumas E, Bihan K, Lebrun-Vignes B, Moslehi J, Spano JP, Laas E, Hotton J, Reyal F, Hamy AS, Salem JE (2024) Clinical spectrum and evolution of immune-checkpoint inhibitors toxicities over a decade-a worldwide perspective. EClinicalMedicine 70:102536","journal-title":"EClinicalMedicine"},{"key":"12_CR63","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.k793","volume":"360","author":"S Baxi","year":"2018","unstructured":"Baxi S, Yang A, Gennarelli RL et al (2018) Immune-related adverse events for anti-PD-1 and anti-PD-L1 drugs: systematic review and meta-analysis. BMJ 360:k793","journal-title":"BMJ"},{"key":"12_CR64","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.ejca.2018.03.006","volume":"96","author":"A Mekki","year":"2018","unstructured":"Mekki A, Dercle L, Lichtenstein P et al (2018) Detection of immune-related adverse events by medical imaging in patients treated with anti-programmed cell death 1. Eur J Cancer 96:91\u2013104","journal-title":"Eur J Cancer"},{"issue":"1","key":"12_CR65","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/CJI.0000000000000300","volume":"43","author":"F Petrelli","year":"2020","unstructured":"Petrelli F, Grizzi G, Ghidini M et al (2020) Immune-related adverse events and survival in solid tumors treated with immune checkpoint inhibitors: a systematic review and meta-analysis. J Immunother 43(1):1\u20137","journal-title":"J Immunother"},{"issue":"2","key":"12_CR66","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1056\/NEJMra1703481","volume":"378","author":"MA Postow","year":"2018","unstructured":"Postow MA, Sidlow R, Hellmann MD (2018) Immune-related adverse events associated with immune checkpoint blockade. N Engl J Med 378(2):158\u2013168","journal-title":"N Engl J Med"},{"issue":"1","key":"12_CR67","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1038\/s41572-020-0160-6","volume":"6","author":"M Ramos-Casals","year":"2020","unstructured":"Ramos-Casals M, Brahmer JR, Callahan MK et al (2020) Immune-related adverse events of checkpoint inhibitors. Nat Rev Dis Primers 6(1):38","journal-title":"Nat Rev Dis Primers"},{"issue":"2","key":"12_CR68","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1111\/1346-8138.13520","volume":"44","author":"Y Nakamura","year":"2017","unstructured":"Nakamura Y, Tanaka R, Asami Y et al (2017) Correlation between vitiligo occurrence and clinical benefit in advanced melanoma patients treated with nivolumab: a multi-institutional retrospective study. J Dermatol 44(2):117\u2013122","journal-title":"J Dermatol"},{"issue":"3","key":"12_CR69","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1001\/jamaoncol.2017.2925","volume":"4","author":"K Haratani","year":"2018","unstructured":"Haratani K, Hayashi H, Chiba Y et al (2018) Association of immune-related adverse events with nivolumab efficacy in non-small-cell lung cancer. JAMA Oncol 4(3):374\u2013378","journal-title":"JAMA Oncol"},{"issue":"1","key":"12_CR70","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1186\/s40425-019-0805-8","volume":"7","author":"S Das","year":"2019","unstructured":"Das S, Johnson DB (2019) Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors. J Immunother Cancer 7(1):306","journal-title":"J Immunother Cancer"},{"issue":"8","key":"12_CR71","doi-asserted-by":"publisher","first-page":"2573","DOI":"10.1007\/s00259-020-05103-3","volume":"48","author":"K Prigent","year":"2021","unstructured":"Prigent K, Lasnon C, Ezine E, Janson M, Coudrais N, Joly E, C\u00e9saire L, Stefan A, Depontville M, Aide N (2021 Jul) Assessing immune organs on 18F-FDG PET\/CT imaging for therapy monitoring of immune checkpoint inhibitors: inter-observer variability, prognostic value and evolution during the treatment course of melanoma patients. Eur J Nucl Med Mol Imaging 48(8):2573\u20132585","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"5","key":"12_CR72","doi-asserted-by":"publisher","first-page":"978","DOI":"10.3390\/diagnostics13050978","volume":"13","author":"M Mangas Losada","year":"2023","unstructured":"Mangas Losada M, Romero Robles L, Mendoza Melero A, Garc\u00eda Meg\u00edas I, Villanueva Torres A, Garrastachu Zumar\u00e1n P, Boulvard Chollet X, Lopci E, Ram\u00edrez Lasanta R, Delgado Bolton RC (2023) [18F]FDG PET\/CT in the evaluation of melanoma patients treated with immunotherapy. Diagnostics (Basel) 13(5):978","journal-title":"Diagnostics (Basel)"},{"key":"12_CR73","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1089\/thy.2019.0250","volume":"30","author":"A Kotwal","year":"2020","unstructured":"Kotwal A, Kottschade L, Ryder M (2020) PD-L1 inhibitor-induced thyroiditis is associated with better overall survival in cancer patients. Thyroid 30:177\u2013184","journal-title":"Thyroid"},{"key":"12_CR74","doi-asserted-by":"publisher","first-page":"667","DOI":"10.2217\/imt-2018-0146","volume":"11","author":"N Lang","year":"2019","unstructured":"Lang N, Dick J, Slynko A, Schulz C, Dimitrakopoulou-Strauss A, Sachpekidis C et al (2019) Clinical significance of signs of autoimmune colitis in (18)F-fluorodeoxyglucose positron emission tomography-computed tomography of 100 stage-IV melanoma patients. Immunotherapy 11:667\u2013676","journal-title":"Immunotherapy"},{"key":"12_CR75","doi-asserted-by":"publisher","first-page":"9523","DOI":"10.1200\/JCO.2016.34.15_suppl.9523","volume":"34","author":"A Wong","year":"2016","unstructured":"Wong A, Callahan J, Beresford J, Herschtal A, Fullerton S, Milne D (2016) Spleen to liver ratio (SLR): novel PET imaging biomarker for prediction of overall survival after ipilimumab and anti-PD1 in patients with metastatic melanoma. J Clin Oncol 34:9523\u20139533","journal-title":"J Clin Oncol"},{"key":"12_CR76","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/s40644-020-00313-2","volume":"20","author":"A Wong","year":"2020","unstructured":"Wong A, Callahan J, Keyaerts M, Neyns B, Mangana J, Aberle S et al (2020) (18)F-FDG PET\/CT based spleen to liver ratio associates with clinical outcome to ipilimumab in patients with metastatic melanoma. Cancer Imaging 20:36","journal-title":"Cancer Imaging"},{"issue":"1","key":"12_CR77","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1148\/rg.2021200093","volume":"41","author":"LB Costa","year":"2021","unstructured":"Costa LB, Queiroz MA, Barbosa FG, Nunes RF, Zaniboni EC, Ruiz MM, Jardim D, Gomes Marin JF, Cerri GG, Buchpiguel CA (2021) Reassessing patterns of response to immunotherapy with PET: from morphology to metabolism. Radiographics 41(1):120\u2013143","journal-title":"Radiographics"},{"key":"12_CR78","doi-asserted-by":"publisher","first-page":"982983","DOI":"10.3389\/fonc.2022.982983","volume":"12","author":"AM Berz","year":"2022","unstructured":"Berz AM, Dromain C, Vietti-Violi N, Boughdad S, Duran R (2022) Tumor response assessment on imaging following immunotherapy. Front Oncol 12:982983. https:\/\/doi.org\/10.3389\/fonc.2022.982983. Erratum in: Front Oncol. 2023 Mar 07;13:1175321","journal-title":"Front Oncol"},{"issue":"18","key":"12_CR79","doi-asserted-by":"publisher","first-page":"2104","DOI":"10.3390\/diagnostics14182104","volume":"14","author":"J Brezun","year":"2024","unstructured":"Brezun J, Aide N, Peroux E, Lamboley J-L, Gutman F, Lussato D, Helissey C (2024) [18F]FDG PET\/CT integration in evaluating immunotherapy for lung cancer: a clinician\u2019s practical approach. Diagnostics 14(18):2104","journal-title":"Diagnostics"},{"key":"12_CR80","doi-asserted-by":"publisher","first-page":"2298","DOI":"10.1007\/s00259-019-04411-7","volume":"46","author":"RD Seban","year":"2019","unstructured":"Seban RD, Nemer JS, Marabelle A, Yeh R, Deutsch E, Ammari S (2019) Prognostic and Theranostic 18F-FDG PET biomarkers for anti-PD1 immunotherapy in metastatic melanoma: association with outcome and transcriptomics. Eur J Nucl Med Mol Imaging 46:2298\u20132310","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"12","key":"12_CR81","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.21037\/atm-20-6833","volume":"9","author":"H Hatic","year":"2021","unstructured":"Hatic H, Sampat D, Goyal G (2021) Immune checkpoint inhibitors in lymphoma: challenges and opportunities. Ann Transl Med 9(12):1037","journal-title":"Ann Transl Med"},{"issue":"4","key":"12_CR82","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa1411087","volume":"372","author":"SM Ansell","year":"2015","unstructured":"Ansell SM, Lesokhin AM, Borrello I, Halwani A, Scott EC, Gutierrez M, Schuster SJ, Millenson MM, Cattry D, Freeman GJ, Rodig SJ, Chapuy B, Ligon AH, Zhu L, Grosso JF, Kim SY, Timmerman JM, Shipp MA, Armand P (2015) PD-1 blockade with nivolumab in relapsed or refractory Hodgkin\u2019s lymphoma. N Engl J Med 372(4):311\u2013319","journal-title":"N Engl J Med"},{"issue":"31","key":"12_CR83","doi-asserted-by":"publisher","first-page":"3733","DOI":"10.1200\/JCO.2016.67.3467","volume":"34","author":"P Armand","year":"2016","unstructured":"Armand P, Shipp MA, Ribrag V, Michot JM, Zinzani PL, Kuruvilla J, Snyder ES, Ricart AD, Balakumaran A, Rose S, Moskowitz CH (2016) Programmed Death-1 blockade with Pembrolizumab in patients with classical Hodgkin lymphoma after Brentuximab Vedotin failure. J Clin Oncol 34(31):3733\u20133739","journal-title":"J Clin Oncol"},{"issue":"1","key":"12_CR84","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.cpet.2019.08.011","volume":"15","author":"E Lopci","year":"2020","unstructured":"Lopci E, Meignan M (2020) Current evidence on PET response assessment to immunotherapy in lymphomas. PET Clin 15(1):23\u201334","journal-title":"PET Clin"},{"key":"12_CR85","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2147\/ITT.S284988","volume":"11","author":"AY Lin","year":"2022","unstructured":"Lin AY, Schnitter JM, Gordon LI (2022) Immune checkpoint blockade for the treatment of Hodgkin lymphoma. Immunotargets Ther 11:1\u201310","journal-title":"Immunotargets Ther"},{"key":"12_CR86","doi-asserted-by":"publisher","first-page":"1368732","DOI":"10.3389\/fonc.2024.1368732","volume":"14","author":"Y Lv","year":"2024","unstructured":"Lv Y, Luo X, Xie Z, Qiu J, Yang J, Deng Y, Long R, Tang G, Zhang C, Zuo J (2024) Prospects and challenges of CAR-T cell therapy combined with ICIs. Front Oncol 14:1368732","journal-title":"Front Oncol"},{"issue":"9","key":"12_CR87","doi-asserted-by":"publisher","first-page":"6536","DOI":"10.1007\/s00330-022-08669-8","volume":"32","author":"G Manson","year":"2022","unstructured":"Manson G, Lemchukwu AC, Mokrane FZ, Lopci E, Aide N, Vercellino L, Houot R, Dercle L (2022) Interpretation of 2-[18F]FDG PET\/CT in Hodgkin lymphoma patients treated with immune checkpoint inhibitors. Eur Radiol 32(9):6536\u20136544","journal-title":"Eur Radiol"},{"key":"12_CR88","first-page":"1","volume":"22","author":"A Castello","year":"2018","unstructured":"Castello A, Grizzi F, Qehajaj D, Rahal D, Lutman F, Lopci E (2018) 18F-FDG PET\/CT for response assessment in Hodgkin lymphoma undergoing immunotherapy with checkpoint inhibitors. Leuk Lymphoma 22:1\u20139","journal-title":"Leuk Lymphoma"},{"key":"12_CR89","doi-asserted-by":"publisher","first-page":"2489","DOI":"10.1182\/blood-2016-05-718528","volume":"128","author":"BD Cheson","year":"2016","unstructured":"Cheson BD, Ansell S, Schwartz L et al (2016) Refinement of the Lugano classification lymphoma response criteria in the era of immunomodulatory therapy. Blood 128:2489\u20132496","journal-title":"Blood"},{"issue":"5","key":"12_CR90","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1007\/s00259-018-4215-9","volume":"46","author":"E Lopci","year":"2019","unstructured":"Lopci E, Meignan M (2019) Deauville score: the Phoenix rising from ashes. Eur J Nucl Med Mol Imaging 46(5):1043\u20131045","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"5","key":"12_CR91","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1200\/JCO.2006.09.2403","volume":"25","author":"BD Cheson","year":"2007","unstructured":"Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ, Coiffier B, Fisher RI, Hagenbeek A, Zucca E, Rosen ST, Stroobants S, Lister TA, Hoppe RT, Dreyling M, Tobinai K, Vose JM, Connors JM, Federico M, Diehl V (2007) International harmonization project on lymphoma. Revised response criteria for malignant lymphoma. J Clin Oncol 25(5):579\u2013586","journal-title":"J Clin Oncol"},{"issue":"27","key":"12_CR92","doi-asserted-by":"publisher","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","volume":"32","author":"BD Cheson","year":"2014","unstructured":"Cheson BD, Fisher RI, Barrington SF, Cavalli F, Schwartz LH, Zucca E, Lister TA, Alliance, Australasian Leukaemia and Lymphoma Group, Eastern Cooperative Oncology Group, European Mantle Cell Lymphoma Consortium, Italian Lymphoma Foundation, European Organisation for Research, Treatment of Cancer\/Dutch Hemato-Oncology Group, Grupo Espa\u00f1ol de M\u00e9dula \u00d3sea, German High-Grade Lymphoma Study Group; German Hodgkin\u2019s Study Group, Japanese Lymphorra Study Group; Lymphoma Study Association, NCIC Clinical Trials Group, Nordic Lymphoma Study Group, Southwest Oncology Group, United Kingdom National Cancer Research Institute (2014) Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol 32(27):3059\u20133068","journal-title":"J Clin Oncol"},{"issue":"10","key":"12_CR93","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1182\/blood.2022019386","volume":"142","author":"P Armand","year":"2023","unstructured":"Armand P, Zinzani PL, Lee HJ, Johnson NA, Brice P, Radford J, Ribrag V, Molin D, Vassilakopoulos TP, Tomita A, von Tresckow B, Shipp MA, Herrera AF, Lin J, Kim E, Chakraborty S, Marinello P, Moskowitz CH (2023) Five-year follow-up of KEYNOTE-087: pembrolizumab monotherapy for relapsed\/refractory classical Hodgkin lymphoma. Blood 142(10):878\u2013886","journal-title":"Blood"},{"key":"12_CR94","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.ejca.2017.12.015","volume":"91","author":"L Dercle","year":"2018","unstructured":"Dercle L, Ammari S, Seban RD, Schwartz LH, Houot R, Labaied N, Mokrane FZ, Lazarovici J, Danu A, Marabelle A, Ribrag V, Michot JM (2018) Kinetics and nadir of responses to immune checkpoint blockade by anti-PD1 in patients with classical Hodgkin lymphoma. Eur J Cancer 91:136\u2013144","journal-title":"Eur J Cancer"},{"issue":"1","key":"12_CR95","doi-asserted-by":"publisher","first-page":"15","DOI":"10.2967\/jnumed.117.193011","volume":"59","author":"L Dercle","year":"2018","unstructured":"Dercle L, Seban RD, Lazarovici J, Schwartz LH, Houot R, Ammari S, Danu A, Edeline V, Marabelle A, Ribrag V, Michot JM (2018) 18F-FDG PET and CT scans detect new imaging patterns of response and progression in patients with Hodgkin lymphoma treated by anti-programmed death 1 immune checkpoint inhibitor. J Nucl Med 59(1):15\u201324","journal-title":"J Nucl Med"},{"key":"12_CR96","doi-asserted-by":"publisher","unstructured":"Rossi C, Gilhodes J, Maerevoet M, Herbaux C, Morschhauser F, Brice P, Garciaz S, Borel C, Ysebaert L, Ob\u00e9ric L, Lazarovici J, Deau B, Dupuis J, Chauchet A, Abraham J, Bijou F, Stamatoullas-Bastard A, Malfuson JV, Golfier C, Laurent C, Pericart S, Traverse-Glehen A, Kanoun S, Filleron T, Casasnovas RO, Ghesqui\u00e8res H (2018) Efficacy of chemotherapy or chemo-anti-PD-1 combination after failed anti-PD-1 therapy for relapsed and refractory Hodgkin lymphoma: a series from Lysa centers. Am J Hematol. https:\/\/doi.org\/10.1002\/ajh.25154","DOI":"10.1002\/ajh.25154"},{"issue":"12","key":"12_CR97","doi-asserted-by":"publisher","first-page":"2305","DOI":"10.1016\/j.bbmt.2019.08.015","volume":"25","author":"T Jain","year":"2019","unstructured":"Jain T, Bar M, Kansagra A, Chong EA, Hashmi SK, Neelapu SS et al (2019) Use of chimeric antigen receptor T cell therapy in clinical practice for relapsed\/refractory aggressive B cell non-Hodgkin lymphoma: an expert panel opinion from the American Society for Transplantation and Cellular Therapy. Biol Blood Marrow Transplant 25(12):2305\u20132321","journal-title":"Biol Blood Marrow Transplant"},{"issue":"6","key":"12_CR98","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1007\/s11307-021-01627-8","volume":"23","author":"A Ruff","year":"2021","unstructured":"Ruff A, Ballard HJ, Pantel AR, Namoglu EC, Hughes ME, Nasta SD et al (2021) 18F-Fluorodeoxyglucose positron emission tomography\/computed tomography following chimeric antigen receptor T-cell therapy in large B-cell lymphoma. Mol Imaging Biol 23(6):818\u2013826","journal-title":"Mol Imaging Biol"},{"issue":"2","key":"12_CR99","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1007\/s00259-014-2961-x","volume":"42","author":"R Boellaard","year":"2015","unstructured":"Boellaard R, Delgado-Bolton R, Oyen WJ, Giammarile F, Tatsch K, Eschner W, Verzijlbergen FJ, Barrington SF, Pike LC, Weber WA, Stroobants S, Delbeke D, Donohoe KJ, Holbrook S, Graham MM, Testanera G, Hoekstra OS, Zijlstra J, Visser E, Hoekstra CJ, Pruim J, Willemsen A, Arends B, Kotzerke J, Bockisch A, Beyer T, Chiti A, Krause BJ, European Association of Nuclear Medicine (EANM) (2015) FDG PET\/CT: EANM procedure guidelines for tumour imaging: version 2.0. Eur J Nucl Med Mol Imaging 42(2):328\u2013354","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"3","key":"12_CR100","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1007\/s00259-021-05551-5","volume":"49","author":"D Cohen","year":"2022","unstructured":"Cohen D, Luttwak E, Beyar-Katz O, Hazut Krauthammer S, Bar-On Y, Amit O, Gold R, Perry C, Avivi I, Ram R, Even-Sapir E (2022) [18F]FDG PET-CT in patients with DLBCL treated with CAR-T cell therapy: a practical approach of reporting pre- and post-treatment studies. Eur J Nucl Med Mol Imaging 49(3):953\u2013962","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"1","key":"12_CR101","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1182\/bloodadvances.2021005807","volume":"6","author":"A Kuhnl","year":"2022","unstructured":"Kuhnl A, Roddie C, Kirkwood AA, Menne T, Cuadrado M, Marzolini MAV, Osborne W, Sanderson R, O\u2019Reilly M, Townsend W, Benjamin R, Potter V, Patten PEM, Yallop D, Voo S, Petrides GS, Mulholland N, Kayani I (2022) Early FDG-PET response predicts CAR-T failure in large B-cell lymphoma. Blood Adv 6(1):321\u2013326","journal-title":"Blood Adv"},{"issue":"1","key":"12_CR102","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/s13045-022-01256-w","volume":"15","author":"WG Breen","year":"2022","unstructured":"Breen WG, Hathcock MA, Young JR, Kowalchuk RO, Bansal R, Khurana A et al (2022) Metabolic characteristics and prognostic differentiation of aggressive lymphoma using one-month post-CAR-T FDG PET\/CT. J Hematol Oncol 15(1):36","journal-title":"J Hematol Oncol"},{"issue":"9","key":"12_CR103","doi-asserted-by":"publisher","first-page":"2867","DOI":"10.1182\/bloodadvances.2021006715","volume":"6","author":"A Al Zaki","year":"2022","unstructured":"Al Zaki A (2022) Day 30 SUVmax predicts progression in patients with lymphoma achieving PR\/SD after CAR T-cell therapy. Blood Adv 6(9):2867\u20132871","journal-title":"Blood Adv"},{"key":"12_CR104","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1016\/j.jcyt.2018.10.003","volume":"20","author":"NN Shah","year":"2018","unstructured":"Shah NN, Nagle SJ, Torigian EA, Farwell MD, Hwang WT, Frey N et al (2018) Early positron emission tomography\/computed tomography as a predictor of response after CTL019 chimeric antigen receptor -T-cell therapy in B-cell non-Hodgkin lymphomas. Cytotherapy 20:1415\u20131418","journal-title":"Cytotherapy"},{"issue":"10","key":"12_CR105","doi-asserted-by":"publisher","first-page":"1230","DOI":"10.1158\/2326-6066.CIR-20-0372","volume":"8","author":"M Dougan","year":"2020","unstructured":"Dougan M (2020) Understanding and overcoming the inflammatory toxicities of immunotherapy. Cancer Immunol Res 8(10):1230\u20131235","journal-title":"Cancer Immunol Res"},{"issue":"1","key":"12_CR106","doi-asserted-by":"publisher","first-page":"e12","DOI":"10.1016\/S2352-3026(18)30192-3","volume":"6","author":"Y Shi","year":"2019","unstructured":"Shi Y, Su H, Song Y, Jiang W, Sun X, Qian W, Zhang W, Gao Y, Jin Z, Zhou J, Jin C, Zou L, Qiu L, Li W, Yang J, Hou M, Zeng S, Zhang Q, Hu J, Zhou H, Xiong Y, Liu P (2019) Safety and activity of sintilimab in patients with relapsed or refractory classical Hodgkin lymphoma (ORIENT-1): a multicentre, single-arm, phase 2 trial. Lancet Haematol 6(1):e12\u2013e19","journal-title":"Lancet Haematol"},{"issue":"1","key":"12_CR107","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1038\/s41467-022-27960-2","volume":"13","author":"M Conroy","year":"2022","unstructured":"Conroy M, Naidoo J (2022) Immune-related adverse events and the balancing act of immunotherapy. Nat Commun 13(1):392","journal-title":"Nat Commun"},{"issue":"4","key":"12_CR108","doi-asserted-by":"publisher","first-page":"225","DOI":"10.14740\/jocmr3750","volume":"11","author":"R Bajwa","year":"2019","unstructured":"Bajwa R, Cheema A, Khan T, Amirpour A, Paul A, Chaughtai S, Patel S, Patel T, Bramson J, Gupta V, Levitt M, Asif A, Hossain MA (2019) Adverse effects of immune checkpoint inhibitors (programmed Death-1 inhibitors and cytotoxic T-lymphocyte-associated Protein-4 inhibitors): results of a retrospective study. J Clin Med Res 11(4):225\u2013236","journal-title":"J Clin Med Res"},{"key":"12_CR109","doi-asserted-by":"publisher","first-page":"1197364","DOI":"10.3389\/fimmu.2023.1197364","volume":"14","author":"B Ibis","year":"2023","unstructured":"Ibis B, Aliazis K, Cao C, Yenyuwadee S, Boussiotis VA (2023) Immune-related adverse effects of checkpoint immunotherapy and implications for the treatment of patients with cancer and autoimmune diseases. Front Immunol 14:1197364","journal-title":"Front Immunol"},{"key":"12_CR110","doi-asserted-by":"publisher","first-page":"20190832","DOI":"10.1259\/bjr.20190832","volume":"93","author":"N Gandy","year":"2020","unstructured":"Gandy N, Arshad MA, Wallitt KL, Dubash S, Khan S, Barwick TD (2020) Immunotherapy-related adverse effects on 18F-FDG PET\/CT imaging. Br J Radiol 93:20190832","journal-title":"Br J Radiol"},{"issue":"4","key":"12_CR111","doi-asserted-by":"publisher","first-page":"e123","DOI":"10.1016\/j.bbmt.2018.12.756","volume":"25","author":"N Frey","year":"2019","unstructured":"Frey N, Porter D (2019) Cytokine release syndrome with chimeric antigen receptor T cell therapy. Biol Blood Marrow Transplant 25(4):e123\u2013e127","journal-title":"Biol Blood Marrow Transplant"},{"key":"12_CR112","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/nrclinonc.2017.148","volume":"15","author":"SS Neelapu","year":"2018","unstructured":"Neelapu SS, Tummala S, Kebriaei P et al (2018) Chimeric antigen receptor T-cell therapy\u2014assessment and management of toxicities. Nat Rev Clin Oncol 15:47\u201362","journal-title":"Nat Rev Clin Oncol"},{"issue":"6","key":"12_CR113","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1038\/s41591-018-0041-7","volume":"24","author":"T Giavridis","year":"2018","unstructured":"Giavridis T, van der Stegen SJC, Eyquem J, Hamieh M, Piersigilli A, Sadelain M (2018) CAR T cell-induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade. Nat Med 24(6):731\u2013738. https:\/\/doi.org\/10.1038\/s41591-018-0041-7","journal-title":"Nat Med"},{"issue":"5","key":"12_CR114","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.3390\/jcm14051451","volume":"14","author":"AG Buciuc","year":"2025","unstructured":"Buciuc AG, Tran S, Weber M, Padilla V, Rueda-Lara M, Espinel Z (2025) Immune effector cell-associated neurotoxicity syndrome after CAR T-cell therapy and other psychiatric manifestations: a review and case series. J Clin Med 14(5):1451","journal-title":"J Clin Med"},{"key":"12_CR115","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.879608","volume":"13","author":"RC Sterner","year":"2022","unstructured":"Sterner RC, Sterner RM (2022) Immune effector cell associated neurotoxicity syndrome in chimeric antigen receptor-T cell therapy. Front Immunol 13:879608","journal-title":"Front Immunol"},{"issue":"6","key":"12_CR116","doi-asserted-by":"publisher","first-page":"1474","DOI":"10.1182\/bloodadvances.2023011896","volume":"8","author":"EH Nie","year":"2024","unstructured":"Nie EH, Su YJ, Baird JH, Agarwal N, Bharadwaj S, Weng WK, Smith M, Dahiya S, Han MH, Dunn JE, Kipp LB, Miklos DB, Scott BJ, Frank MJ (2024) Clinical features of neurotoxicity after CD19 CAR T-cell therapy in mantle cell lymphoma. Blood Adv 8(6):1474\u20131486","journal-title":"Blood Adv"},{"issue":"3","key":"12_CR117","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1016\/j.neurol.2021.01.019","volume":"178","author":"V Vernier","year":"2022","unstructured":"Vernier V, Ursu R, Belin C, Maillet D, Thieblemont C, Carpentier AF (2022) Hypometabolism on brain FDG-PET as a marker for neurotoxicity after CAR T-cell therapy: a case report. Rev Neurol (Paris) 178(3):282\u2013284","journal-title":"Rev Neurol (Paris)"},{"issue":"31","key":"12_CR118","doi-asserted-by":"publisher","first-page":"3884","DOI":"10.1200\/JCO.2012.42.4887","volume":"30","author":"SM Knowles","year":"2012","unstructured":"Knowles SM, Wu A (2012) Advances in immuno\u2013positron emission tomography: antibodies for molecular imaging in oncology. J Clin Oncol 30(31):3884\u20133892","journal-title":"J Clin Oncol"},{"issue":"1","key":"12_CR119","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1038\/s41420-023-01778-3","volume":"10","author":"T Zhang","year":"2024","unstructured":"Zhang T, Lei H, Chen X, Dou Z, Yu B, Su W, Wang W, Jin X, Katsube T, Wang B, Zhang H, Li Q, Di C (2024) Carrier systems of radiopharmaceuticals and the application in cancer therapy. Cell Death Discov 10(1):16","journal-title":"Cell Death Discov"},{"issue":"1","key":"12_CR120","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.annonc.2021.11.003","volume":"33","author":"AM Menzies","year":"2022","unstructured":"Menzies AM, Lastoria S (2022) PET imaging for cancer immunotherapy: the Immuno-PET. Ann Oncol 33(1):13\u201314","journal-title":"Ann Oncol"},{"issue":"1","key":"12_CR121","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1038\/s41698-022-00263-x","volume":"6","author":"F Hegi-Johnson","year":"2022","unstructured":"Hegi-Johnson F, Rudd S, Hicks RJ, De Ruysscher D, Trapani JA, John T, Donnelly P, Blyth B, Hanna G, Everitt S, Roselt P, MacManus MP (2022) Imaging immunity in patients with cancer using positron emission tomography. NPJ Precis Oncol 6(1):24","journal-title":"NPJ Precis Oncol"},{"issue":"5","key":"12_CR122","doi-asserted-by":"publisher","first-page":"1782","DOI":"10.1021\/acs.molpharmaceut.7b00056","volume":"14","author":"EB Ehlerding","year":"2017","unstructured":"Ehlerding EB, England CG, Majewski RL, Valdovinos HF, Jiang D, Liu G, McNeel DG, Nickles RJ, Cai W (2017) ImmunoPET imaging of CTLA-4 expression in mouse models of non-small cell lung cancer. Mol Pharm 14(5):1782\u20131789","journal-title":"Mol Pharm"},{"issue":"2","key":"12_CR123","doi-asserted-by":"publisher","first-page":"107","DOI":"10.5582\/bst.2021.01017","volume":"15","author":"F Gao","year":"2021","unstructured":"Gao F, Zhao W, Li M et al (2021) Role of circulating tumor cell detection in differentiating tumor recurrence from treatment necrosis of brain gliomas. Biosci Trends 15(2):107\u2013117","journal-title":"Biosci Trends"},{"issue":"8","key":"12_CR124","doi-asserted-by":"publisher","first-page":"3787","DOI":"10.1021\/acs.chemrev.9b00738","volume":"120","author":"W Wei","year":"2020","unstructured":"Wei W, Rosenkrans ZT, Liu J, Huang G, Luo QY, Cai W (2020) ImmunoPET: concept, design, and applications. Chem Rev 120(8):3787\u20133851","journal-title":"Chem Rev"},{"issue":"1","key":"12_CR125","first-page":"53","volume":"9","author":"EB Ehlerding","year":"2019","unstructured":"Ehlerding EB, Lee HJ, Jiang D, Ferreira CA, Zahm CD, Huang P, Engle JW, McNeel DG, Cai W (2019) Antibody and fragment-based PET imaging of CTLA-4+ T-cells in humanized mouse models. Am J Cancer Res 9(1):53\u201363","journal-title":"Am J Cancer Res"},{"issue":"1","key":"12_CR126","doi-asserted-by":"publisher","first-page":"4664","DOI":"10.1038\/s41467-018-07131-y","volume":"9","author":"AN Niemeijer","year":"2018","unstructured":"Niemeijer AN, Leung D, Huisman MC, Bahce I, Hoekstra OS, van Dongen GAMS, Boellaard R, Du S, Hayes W, Smith R, Windhorst AD, Hendrikse NH, Poot A, Vugts DJ, Thunnissen E, Morin P, Lipovsek D, Donnelly DJ, Bonacorsi SJ, Velasquez LM, de Gruijl TD, Smit EF, de Langen AJ (2018) Whole body PD-1 and PD-L1 positron emission tomography in patients with non-small-cell lung cancer. Nat Commun 9(1):4664","journal-title":"Nat Commun"},{"issue":"3","key":"12_CR127","doi-asserted-by":"publisher","first-page":"359","DOI":"10.2967\/jnumed.121.262622","volume":"63","author":"H Westdorp","year":"2022","unstructured":"Westdorp H, Verhoeff SR, Gotthardt M, van Herpen CML, van MM, Heuvel D, Heskamp S, Aarntzen EHJG. (2022) Toward a better understanding of immune checkpoint inhibitor radiolabeled PET imaging studies. J Nucl Med 63(3):359\u2013361","journal-title":"J Nucl Med"},{"issue":"10","key":"12_CR128","doi-asserted-by":"publisher","first-page":"1523","DOI":"10.2967\/jnumed.121.263470","volume":"63","author":"SR Verhoeff","year":"2022","unstructured":"Verhoeff SR, van de Donk PP, Aarntzen EHJG, Oosting SF, Brouwers AH, Miedema IHC, Voortman J, der Houven M-v, van Oordt WC, Boellaard R, Vriens D, Slingerland M, Hermsen R, Grunsven IVE, Heskamp S, van Herpen CML (2022) 89Zr-DFO-Durvalumab PET\/CT before Durvalumab treatment in patients with recurrent or metastatic head and neck cancer. J Nucl Med 63(10):1523\u20131530","journal-title":"J Nucl Med"},{"issue":"11","key":"12_CR129","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2021-056708","volume":"12","author":"F Hegi-Johnson","year":"2022","unstructured":"Hegi-Johnson F, Rudd SE, Wichmann C, Akhurst T, Roselt P, Trinh J, John T, Devereux L, Donnelly PS, Hicks R, Scott AM, Steinfort D, Fox S, Blyth B, Parakh S, Hanna GG, Callahan J, Burbury K, MacManus M (2022) ImmunoPET: IMaging of cancer imMUNOtherapy targets with positron emission tomography: a phase 0\/1 study characterising PD-L1 with 89Zr-durvalumab (MEDI4736) PET\/CT in stage III NSCLC patients receiving chemoradiation study protocol. BMJ Open 12(11):e056708","journal-title":"BMJ Open"},{"key":"12_CR130","doi-asserted-by":"publisher","first-page":"1272570","DOI":"10.3389\/fimmu.2023.1272570","volume":"14","author":"A Puyalto","year":"2023","unstructured":"Puyalto A, Rodr\u00edguez-Rem\u00edrez M, L\u00f3pez I, Iribarren F, Sim\u00f3n JA, Ecay M, Collantes M, Vilalta-Lacarra A, Francisco-Cruz A, Sol\u00f3rzano JL, Sandiego S, Pe\u00f1uelas I, Calvo A, Ajona D, Gil-Bazo I (2023) A novel [89Zr]-anti-PD-1-PET-CT to assess response to PD-1\/PD-L1 blockade in lung cancer. Front Immunol 14:1272570","journal-title":"Front Immunol"},{"issue":"5","key":"12_CR131","first-page":"720","volume":"63","author":"MD Farwell","year":"2022","unstructured":"Farwell MD, Gamache RF, Babazada H, Hellmann MD, Harding JJ, Korn R, Mascioni A, Le W, Wilson I, Gordon MS, Wu AM, Ulaner GA, Wolchok JD, Postow MA, Pandit-Taskar N (2022) CD8-targeted PET imaging of tumor-infiltrating T cells in patients with cancer: a phase I first-in-humans study of 89Zr-Df-IAB22M2C, a radiolabeled anti-CD8 minibody. J Nucl Med 63(5):720\u2013726","journal-title":"J Nucl Med"},{"issue":"4","key":"12_CR132","doi-asserted-by":"publisher","first-page":"512","DOI":"10.2967\/jnumed.119.229781","volume":"61","author":"N Pandit-Taskar","year":"2020","unstructured":"Pandit-Taskar N, Postow MA, Hellmann MD, Harding JJ, Barker CA, O\u2019Donoghue JA, Ziolkowska M, Ruan S, Lyashchenko SK, Tsai F, Farwell M, Mitchell TC, Korn R, Le W, Lewis JS, Weber WA, Behera D, Wilson I, Gordon M, Wu AM, Wolchok JD (2020) First-in-humans imaging with 89Zr-Df-IAB22M2C anti-CD8 Minibody in patients with solid malignancies: preliminary pharmacokinetics, biodistribution, and lesion targeting. J Nucl Med 61(4):512\u2013519","journal-title":"J Nucl Med"},{"key":"12_CR133","doi-asserted-by":"publisher","first-page":"2601","DOI":"10.1038\/s41591-022-02084-8","volume":"28","author":"L Kist de Ruijter","year":"2022","unstructured":"Kist de Ruijter L, van de Donk PP, Hooiveld-Noeken JS, Giesen D, Elias SG, Lub-de Hooge MN, Oosting SF, Jalving M, Timens W, Brouwers AH et al (2022) Whole-body CD8+ T cell visualization before and during cancer immunotherapy: a phase 1\/2 trial. Nat Med 28:2601\u20132610","journal-title":"Nat Med"},{"issue":"7","key":"12_CR134","doi-asserted-by":"publisher","first-page":"1958","DOI":"10.1158\/1078-0432.CCR-20-3243","volume":"27","author":"VL Nagle","year":"2021","unstructured":"Nagle VL, Henry KE, Hertz CAJ, Graham MS, Campos C, Parada LF, Pandit-Taskar N, Schietinger A, Mellinghoff IK, Lewis JS (2021) Imaging tumor-infiltrating lymphocytes in brain tumors with [64Cu]cu-NOTA-anti-CD8 PET. Clin Cancer Res 27(7):1958\u20131966","journal-title":"Clin Cancer Res"},{"issue":"13","key":"12_CR135","doi-asserted-by":"publisher","first-page":"4394","DOI":"10.1007\/s00259-022-05903-9","volume":"49","author":"Y Wang","year":"2022","unstructured":"Wang Y, Wang C, Huang M, Qin S, Zhao J, Sang S, Zheng M, Bian Y, Huang C, Zhang H, Guo L, Jiang J, Xu C, Dai N, Zheng Y, Han J, Yang M, Xu T, Miao L (2022) Pilot study of a novel nanobody 68 Ga-NODAGA-SNA006 for instant PET imaging of CD8+ T cells. Eur J Nucl Med Mol Imaging 49(13):4394\u20134405","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"6","key":"12_CR136","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1007\/s11307-021-01621-0","volume":"23","author":"KP Maresca","year":"2021","unstructured":"Maresca KP, Chen J, Mathur D, Giddabasappa A, Root A, Narula J, King L, Schaer D, Golas J, Kobylarz K, Rosfjord E, Keliher E, Chen L, Ram S, Pickering EH, Hardwick JS, Rejto PA, Hussein A, Ilovich O, Staton K, Wilson I, McCarthy TJ (2021) Preclinical evaluation of 89Zr-Df-IAB22M2C PET as an imaging biomarker for the development of the GUCY2C-CD3 bispecific PF-07062119 as a T cell engaging therapy. Mol Imaging Biol 23(6):941\u2013951","journal-title":"Mol Imaging Biol"},{"issue":"16","key":"12_CR137","doi-asserted-by":"publisher","DOI":"10.1172\/JCI161065","volume":"132","author":"H Zhou","year":"2022","unstructured":"Zhou H, Wang Y, Xu H, Shen X, Zhang T, Zhou X, Zeng Y, Li K, Zhang L, Zhu H, Yang X, Li N, Yang Z, Liu Z (2022) Noninvasive interrogation of CD8+ T cell effector function for monitoring early tumor responses to immunotherapy. J Clin Invest 132(16):e161065","journal-title":"J Clin Invest"},{"issue":"9","key":"12_CR138","doi-asserted-by":"publisher","first-page":"2318","DOI":"10.1158\/0008-5472.CAN-16-3346","volume":"77","author":"BM Larimer","year":"2017","unstructured":"Larimer BM, Wehrenberg-Klee E, Dubois F, Mehta A, Kalomeris T, Flaherty K, Boland G, Mahmood U (2017) Granzyme B PET imaging as a predictive biomarker of immunotherapy response. Cancer Res 77(9):2318\u20132327","journal-title":"Cancer Res"},{"issue":"4","key":"12_CR139","doi-asserted-by":"publisher","first-page":"1196","DOI":"10.1158\/1078-0432.CCR-18-2407","volume":"25","author":"BM Larimer","year":"2019","unstructured":"Larimer BM, Bloch E, Nesti S, Austin EE, Wehrenberg-Klee E, Boland G, Mahmood U (2019) The effectiveness of checkpoint inhibitor combinations and administration timing can be measured by Granzyme B PET imaging. Clin Cancer Res 25(4):1196\u20131205","journal-title":"Clin Cancer Res"},{"issue":"10","key":"12_CR140","doi-asserted-by":"publisher","first-page":"1638","DOI":"10.1021\/acscentsci.1c00529","volume":"7","author":"N Zhao","year":"2021","unstructured":"Zhao N, Bardine C, Louren\u00e7o AL, Wang YH, Huang Y, Cleary SJ, Wilson DM, Oh DY, Fong L, Looney MR, Evans MJ, Craik CS (2021) In vivo measurement of Granzyme proteolysis from activated immune cells with PET. ACS Cent Sci 7(10):1638\u20131649","journal-title":"ACS Cent Sci"},{"key":"12_CR141","first-page":"A52","volume":"9","author":"J Levi","year":"2021","unstructured":"Levi J, Perk T, Huynh L et al (2021) AI-assisted whole-body assessment of immunotherapy response using [18F]F-AraG, a PET agent for activated T cells. J Immuno Ther Cancer 9:A52","journal-title":"J Immuno Ther Cancer"},{"key":"12_CR142","doi-asserted-by":"publisher","first-page":"340","DOI":"10.2967\/jnumed.109.070946","volume":"51","author":"A Ribas","year":"2010","unstructured":"Ribas A, Benz MR, Allen-Auerbach MS, Radu C, Chmielowski B, Seja E, Williams JL, Gomez-Navarro J, McCarthy T, Czernin J (2010) Imaging of CTLA4 blockade-induced cell replication with (18)F-FLT PET in patients with advanced melanoma treated with tremelimumab. J Nucl Med 51:340\u2013346","journal-title":"J Nucl Med"},{"issue":"1","key":"12_CR143","first-page":"tzad004","volume":"6","author":"S Majumder","year":"2023","unstructured":"Majumder S, Katz S, Kontos D, Roshkovan L (2023) State of the art: radiomics and radiomics-related artificial intelligence on the road to clinical translation. BJR Open 6(1):tzad004","journal-title":"BJR Open"},{"issue":"10","key":"12_CR144","first-page":"1248","volume":"14","author":"A Maniaci","year":"2024","unstructured":"Maniaci A, Lavalle S, Gagliano C, Lentini M, Masiello E, Parisi F, Iannella G, Cilia ND, Salerno V, Cusumano G, La Via L (2024) The integration of Radiomics and artificial intelligence in modern medicine. Life (Basel) 14(10):1248","journal-title":"Life (Basel)"},{"issue":"9","key":"12_CR145","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1016\/S1470-2045(18)30413-3","volume":"19","author":"R Sun","year":"2018","unstructured":"Sun R, Limkin EJ, Vakalopoulou M et al (2018) A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study. Lancet Oncol 19(9):1180\u20131191","journal-title":"Lancet Oncol"},{"issue":"2","key":"12_CR146","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-001429","volume":"8","author":"R Sun","year":"2020","unstructured":"Sun R, Sundahl N, Hecht M et al (2020) Radiomics to predict outcomes and abscopal response of patients with cancer treated with immunotherapy combined with radiotherapy using a validated signature of CD8 cells. J Immunother Cancer 8(2):e001429","journal-title":"J Immunother Cancer"},{"key":"12_CR147","doi-asserted-by":"publisher","first-page":"1450020","DOI":"10.3389\/fonc.2024.1450020","volume":"14","author":"D Xue","year":"2024","unstructured":"Xue D, Li N, Yang J, Men K, Li L, Jiang H, Zhao X, Zhang S (2024) Sarcopenia predicts immune-related adverse events due to anti-PD-1\/PD-L1 therapy in patients with advanced lung cancer. Front Oncol 14:1450020","journal-title":"Front Oncol"},{"key":"12_CR148","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.726257","volume":"11","author":"S Li","year":"2021","unstructured":"Li S, Wang T, Tong G, Li X, You D, Cong M (2021) Prognostic impact of sarcopenia on clinical outcomes in malignancies treated with immune checkpoint inhibitors: a systematic review and meta-analysis. Front Oncol 11:726257","journal-title":"Front Oncol"},{"key":"12_CR149","doi-asserted-by":"publisher","DOI":"10.1016\/j.nut.2022.111829","volume":"105","author":"Y Deng","year":"2023","unstructured":"Deng Y, Zhao L, Huang X, Zeng Y, Xiong Z, Zuo M (2023) Contribution of skeletal muscle to cancer immunotherapy: a focus on muscle function, inflammation, and microbiota. Nutrition 105:111829","journal-title":"Nutrition"},{"key":"12_CR150","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.lungcan.2020.03.003","volume":"143","author":"B Roch","year":"2020","unstructured":"Roch B, Coffy A, Jean-Baptiste S, Palaysi E, Daures JP, Pujol JL, Bommart S (2020) Cachexia \u2013 sarcopenia as a determinant of disease control rate and survival in non-small lung cancer patients receiving immune-checkpoint inhibitors. Lung Cancer 143:19\u201326","journal-title":"Lung Cancer"},{"issue":"4","key":"12_CR151","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.3390\/cancers15041076","volume":"15","author":"C Madeddu","year":"2023","unstructured":"Madeddu C, Busquets S, Donisi C, Lai E, Pretta A, L\u00f3pez-Soriano FJ, Argil\u00e9s JM, Scartozzi M, Macci\u00f2 A (2023) Effect of cancer-related cachexia and associated changes in nutritional status, inflammatory status, and muscle mass on immunotherapy efficacy and survival in patients with advanced non-small cell lung cancer. Cancers (Basel) 15(4):1076","journal-title":"Cancers (Basel)"},{"issue":"2","key":"12_CR152","doi-asserted-by":"publisher","first-page":"487","DOI":"10.3390\/cancers12020487","volume":"12","author":"A Castello","year":"2020","unstructured":"Castello A, Carbone FG, Rossi S, Monterisi S, Federico D, Toschi L, Lopci E (2020) Circulating tumor cells and metabolic parameters in NSCLC patients treated with checkpoint inhibitors. Cancers (Basel) 12(2):487","journal-title":"Cancers (Basel)"},{"issue":"1","key":"12_CR153","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/s43556-025-00257-8","volume":"6","author":"H Yin","year":"2025","unstructured":"Yin H, Zhang M, Zhang Y, Zhang X, Zhang X, Zhang B (2025) Liquid biopsies in cancer. Mol Biomed 6(1):18","journal-title":"Mol Biomed"},{"issue":"6","key":"12_CR154","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.3390\/cancers12061373","volume":"12","author":"A Castello","year":"2020","unstructured":"Castello A, Rossi S, Toschi L, Mansi L, Lopci E (2020) Soluble PD-L1 in NSCLC patients treated with checkpoint inhibitors and its correlation with metabolic parameters. Cancers (Basel) 12(6):1373","journal-title":"Cancers (Basel)"},{"issue":"1","key":"12_CR155","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1186\/s12967-023-03960-8","volume":"21","author":"S Connal","year":"2023","unstructured":"Connal S, Cameron JM, Sala A, Brennan PM, Palmer DS, Palmer JD, Perlow H, Baker MJ (2023) Liquid biopsies: the future of cancer early detection. J Transl Med 21(1):118","journal-title":"J Transl Med"},{"issue":"10","key":"12_CR156","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1080\/14737159.2024.2408744","volume":"24","author":"SW Fu","year":"2024","unstructured":"Fu SW, Tang C, Tan X, Srivastava S (2024) Liquid biopsy for early cancer detection: technological revolutions and clinical dilemma. Expert Rev Mol Diagn 24(10):937\u2013955","journal-title":"Expert Rev Mol Diagn"},{"issue":"3","key":"12_CR157","doi-asserted-by":"publisher","first-page":"349","DOI":"10.3390\/genes12030349","volume":"12","author":"I Martins","year":"2021","unstructured":"Martins I, Ribeiro IP, Jorge J, Gon\u00e7alves AC, Sarmento-Ribeiro AB, Melo JB, Carreira IM (2021) Liquid biopsies: applications for cancer diagnosis and monitoring. Genes (Basel) 12(3):349","journal-title":"Genes (Basel)"},{"key":"12_CR158","doi-asserted-by":"publisher","first-page":"947","DOI":"10.3892\/or.2012.1649","volume":"27","author":"R Shimada","year":"2012","unstructured":"Shimada R, Iinuma H, Akahane T et al (2012) Prognostic significance of CTCs and CSCs of tumor drainage vein blood in dukes\u2019 stage B and C colorectal cancer patients. Oncol Rep 27:947\u2013953","journal-title":"Oncol Rep"},{"key":"12_CR159","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2020.103109","volume":"155","author":"LS Pessoa","year":"2020","unstructured":"Pessoa LS, Heringer M, Ferrer VP (2020) ctDNA as a cancer biomarker: a broad overview. Crit Rev Oncol Hematol 155:103109","journal-title":"Crit Rev Oncol Hematol"},{"key":"12_CR160","doi-asserted-by":"publisher","first-page":"E968","DOI":"10.1073\/pnas.1521230113","volume":"113","author":"J Kowal","year":"2016","unstructured":"Kowal J, Arras G, Colombo M et al (2016) Proteomic comparison defines novel markers to characterize heterogeneous populations of extracellular vesicle subtypes. Proc Natl Acad Sci USA 113:E968\u2013E977","journal-title":"Proc Natl Acad Sci USA"},{"issue":"1","key":"12_CR161","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1002\/jmrs.720","volume":"71","author":"CM Post","year":"2024","unstructured":"Post CM, Ohaegbulam KC, Mitin T (2024) From planned neck dissection to PET response to circulating tumour DNA: changes in post-treatment assessment of HPV-driven oropharyngeal cancer\u2020. J Med Radiat Sci 71(1):21\u201325","journal-title":"J Med Radiat Sci"},{"issue":"10","key":"12_CR162","doi-asserted-by":"publisher","first-page":"3250","DOI":"10.1007\/s00259-021-05260-z","volume":"48","author":"F Zhang","year":"2021","unstructured":"Zhang F, Wu X, Zhu J et al (2021) 18F-FDG PET\/CT and circulating tumor cells in treatment-naive patients with non-small-cell lung cancer. Eur J Nucl Med Mol Imaging 48(10):3250\u20133259","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"2","key":"12_CR163","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1111\/bjh.19162","volume":"204","author":"E Calabretta","year":"2024","unstructured":"Calabretta E, di Trani M, Corrado F et al (2024) Baseline circulating tumour DNA and interim PET predict response in relapsed\/refractory classical Hodgkin lymphoma. Br J Haematol 204(2):514\u2013524","journal-title":"Br J Haematol"},{"issue":"7","key":"12_CR164","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1182\/bloodadvances.2017015164","volume":"2","author":"MH Delfau-Larue","year":"2018","unstructured":"Delfau-Larue MH, van der Gucht A, Dupuis J et al (2018) Total metabolic tumor volume, circulating tumor cells, cell-free DNA: distinct prognostic value in follicular lymphoma. Blood Adv 2(7):807\u2013816","journal-title":"Blood Adv"},{"issue":"1","key":"12_CR165","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1182\/bloodadvances.2023011890","volume":"8","author":"D Ikeda","year":"2024","unstructured":"Ikeda D, Terao T, Oura M et al (2024) Analysis of baseline circulating tumor cells integrated with PET\/CT findings in transplant-ineligible multiple myeloma. Blood Adv 8(1):37\u201346","journal-title":"Blood Adv"},{"issue":"2","key":"12_CR166","doi-asserted-by":"publisher","first-page":"e120","DOI":"10.1097\/SLA.0000000000005177","volume":"276","author":"CS Cabalag","year":"2022","unstructured":"Cabalag CS, Yates M, Corrales MB et al (2022) Potential clinical utility of a targeted circulating tumor DNA assay in esophageal adenocarcinoma. Ann Surg 276(2):e120\u2013e126","journal-title":"Ann Surg"},{"issue":"10","key":"12_CR167","doi-asserted-by":"publisher","first-page":"1366","DOI":"10.2967\/jnumed.118.222919","volume":"60","author":"E Woff","year":"2019","unstructured":"Woff E, Kehagias P, Vandeputte C et al (2019) Combining 18F-FDG PET\/CT-based metabolically active tumor volume and circulating cell-free DNA significantly improves outcome prediction in Chemorefractory metastatic colorectal cancer. J Nucl Med 60(10):1366\u20131372","journal-title":"J Nucl Med"},{"issue":"9","key":"12_CR168","doi-asserted-by":"publisher","first-page":"2962","DOI":"10.1016\/j.transproceed.2016.07.035","volume":"48","author":"P Ramirez","year":"2016","unstructured":"Ramirez P, S\u00e1enz L, Cascales-Campos PA et al (2016) Oncological evaluation by positron-emission tomography, circulating tumor cells and alpha fetoprotein in patients with hepatocellular carcinoma on the waiting list for liver transplantation. Transplant Proc 48(9):2962\u20132965","journal-title":"Transplant Proc"},{"issue":"3","key":"12_CR169","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1038\/s41416-021-01507-6","volume":"126","author":"G Marsavela","year":"2022","unstructured":"Marsavela G, McEvoy AC, Pereira MR et al (2022) Detection of clinical progression through plasma ctDNA in metastatic melanoma patients: a comparison to radiological progression. Br J Cancer 126(3):401\u2013408","journal-title":"Br J Cancer"},{"issue":"6","key":"12_CR170","doi-asserted-by":"publisher","first-page":"1613","DOI":"10.1007\/s00259-019-04672-2","volume":"47","author":"C Schmidkonz","year":"2020","unstructured":"Schmidkonz C, Krumbholz M, Atzinger A et al (2020) Assessment of treatment responses in children and adolescents with Ewing sarcoma with metabolic tumor parameters derived from 18F-FDG-PET\/CT and circulating tumor DNA. Eur J Nucl Med Mol Imaging 47(6):1613","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"10","key":"12_CR171","doi-asserted-by":"publisher","first-page":"606.e9","DOI":"10.1016\/j.urolonc.2017.05.021","volume":"35","author":"J Abrahamsson","year":"2017","unstructured":"Abrahamsson J, Aaltonen K, Engilbertsson H et al (2017) Circulating tumor cells in patients with advanced urothelial carcinoma of the bladder: association with tumor stage, lymph node metastases, FDG-PET findings, and survival. Urol Oncol 35(10):606.e9\u2013606.e16","journal-title":"Urol Oncol"}],"container-title":["Recent Results in Cancer Research","Molecular Imaging in Oncology - Volume 2"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/978-3-032-21415-7_12","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T11:02:19Z","timestamp":1779361339000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/978-3-032-21415-7_12"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"ISBN":["9783032214140","9783032214157"],"references-count":171,"URL":"https:\/\/doi.org\/10.1007\/978-3-032-21415-7_12","relation":{},"ISSN":["0080-0015","2197-6767"],"issn-type":[{"value":"0080-0015","type":"print"},{"value":"2197-6767","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026]]},"assertion":[{"value":"22 May 2026","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}}]}}